Other transplantation-related outcomes in UCBT recipients by prevention strategy (n = 72)
| Outcomes . | Intensive, n = 43 n (%) . | Standard, n = 29 n (%) . | P* . |
|---|---|---|---|
| Time to engraftment† | 20 | 20 | .49§ |
| Median days (IQR) | (17-28) | (14-29) | |
| Time to platelets ≥ 20 000† | 36 | 34 | .37 |
| Median days (IQR) | (31-50) | (29-45) | |
| Acute GVHD‡ | |||
| Grade II-IV | 28 (74) | 25 (86) | .21 |
| Grade III-IV | 8 (21) | 10 (34) | .22§ |
| Renal function | |||
| Mean max creatinine (SD) | 1.8 (1.2) | 1.6 (1.0) | .47 |
| Acute kidney injury‡ | |||
| × 2 baseline | 28 (65) | 18 (62) | .81 |
| × 3 baseline | 16 (37) | 7 (24) | .31 |
| Nonrelapse mortality | |||
| First 100 days | 8 (19) | 2 (7) | .30¶ |
| 1 year | 11 (26) | 6 (21) | .63¶ |
| Outcomes . | Intensive, n = 43 n (%) . | Standard, n = 29 n (%) . | P* . |
|---|---|---|---|
| Time to engraftment† | 20 | 20 | .49§ |
| Median days (IQR) | (17-28) | (14-29) | |
| Time to platelets ≥ 20 000† | 36 | 34 | .37 |
| Median days (IQR) | (31-50) | (29-45) | |
| Acute GVHD‡ | |||
| Grade II-IV | 28 (74) | 25 (86) | .21 |
| Grade III-IV | 8 (21) | 10 (34) | .22§ |
| Renal function | |||
| Mean max creatinine (SD) | 1.8 (1.2) | 1.6 (1.0) | .47 |
| Acute kidney injury‡ | |||
| × 2 baseline | 28 (65) | 18 (62) | .81 |
| × 3 baseline | 16 (37) | 7 (24) | .31 |
| Nonrelapse mortality | |||
| First 100 days | 8 (19) | 2 (7) | .30¶ |
| 1 year | 11 (26) | 6 (21) | .63¶ |
IQR indicates interquartile range; UCBT, umbilical cord blood transplantation.
P values calculated with the Fisher exact probability test for categorical variables and Wilcoxon-rank sum for continuous variables, unless otherwise specified.
Only in patients who engrafted.
When calculated by time-to-event analysis P = .07 (Gray test).
When calculated by time to event analysis P = .20 (Gray test).
Acute kidney injury as defined by ≥ 2 times baseline creatinine or ≥ 3 times baseline, during the first 100 days.29
Calculated by log-rank.